The purpose of this study is to determine, in obese insulin resistant subjects, the effect of maraviroc therapy, a selective antagonist of the human chemokine receptor CCR5, on:~Plasma triglyceride concentration~Plasma HDL-cholesterol and LDL-cholesterol concentrations~Plasma markers of cardiometabolic risk and inflammation
The purpose of this study is to determine the effect of maraviroc therapy in obese insulin resistant subjects on:~Plasma triglyceride concentration~Plasma HDL-cholesterol and LDL-cholesterol concentrations~Plasma markers of cardiometabolic risk and inflammation